Key result
Provided text contains no clinical data comparing 18-month versus 6-month rivaroxaban for recurrent VTE.
Why the study?
It was uncertain whether the superiority of 18-month vs 6-month rivaroxaban for cancer-associated acute low-risk pulmonary embolism applied across different stages of chemotherapy exposure.
Does 18-month rivaroxaban treatment reduce recurrent VTE compared to 6-month treatment in patients with cancer-associated low-risk PE regardless of chemotherapy status?
Does 18-month rivaroxaban treatment reduce recurrent VTE compared to 6-month treatment in patients with cancer-associated low-risk PE regardless of chemotherapy status?
Extended 18-month rivaroxaban therapy may reduce recurrent VTE risk in cancer-associated low-risk PE regardless of chemotherapy status, without significantly increasing major bleeding.
Answers are grounded in this paper and cite their sources.
May support extended rivaroxaban across chemotherapy strata in cancer-associated PE; leaves open confirmation in larger studies.
The ONCO PE trial demonstrated the superiority of 18-month compared with 6-month rivaroxaban treatment for cancer-associated acute low-risk pulmonary embolism (PE) in reducing recurrent venous thromboembolism (VTE). However, it was uncertain whether the results could be applicable to patients in different stages of chemotherapy exposure. In this prespecified subgroup analysis of the ONCO PE trial, patients were classified into chemotherapy (n = 107) and nonchemotherapy (n = 71) subgroups based on the status of chemotherapy exposure at the PE diagnosis. We compared the primary endpoint of recurrent VTE and the major secondary endpoint of major bleeding between the 18- and 6-month rivaroxaban treatment groups in each subgroup. The cumulative 18-month incidence rate of recurrent VTE was numerically lower in the 18-month rivaroxaban group than in the 6-month rivaroxaban group among both the chemotherapy (6.6% vs. 20.8%, log-rank p = 0.06) and nonchemotherapy subgroups (6.6% vs. 23.4%, log-rank p = 0.09) without a significant interaction between chemotherapy exposure and treatment duration (p-interaction = 0.94). There was no significant difference in the cumulative 18-month incidence of major bleeding between the 18- and 6-month rivaroxaban groups among either the chemotherapy (9.7% vs. 4.1%, log-rank p = 0.29) or nonchemotherapy subgroup (6.2% vs. 8.0%, log-rank p = 0.73) without a significant interaction between chemotherapy exposure and treatment duration (p-interaction = 0.36). Extended anticoagulation therapy for patients with cancer-associated acute low-risk PE might have a potential benefit in reducing thrombotic risk irrespective of the status of chemotherapy exposure without a significantly increased risk of major bleeding.
No takes yet. Share an insight, caveat, or question.
Xiong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: